

TruScreen Key Investment Highlights

TruScreen Group Limited (NZX/ASX:TRU) provides a world class, real time cervical cancer screening medical device. TruScreen® Ultra is portable, affordable, easy to use, painless and can be operated by non-doctor. TruScreen technology is recommended by the Chinese Obstetrics and Gynecological Association's Blue Book and features in the Chinese Society of Colposcopy and Cervical Pathology National Screening Guidelines. TruScreen® Ultra device is registered in 20 countries and commercially used in China, Vietnam, Mexico, Zimbabwe, Russia and Poland, and Saudi Arabia.

Largest market and opportunity – China

- ▶ **China NZ\$1.78 M sales 9 months YTD December 2023, 77% up on prior year**
- ▶ Rapid China growth supported by **Made in China (MIC)** status secured in FY 2022 –preferred market access
- ▶ MIC creates strong barrier to entry for potential, future competitors
- ▶ TruScreen recommended by **COGA BLUE BOOK**, a Consensus, by the top country gynaecologists
- ▶ **CSCCP Specialist Guideline** features TruScreen technology

High growth opportunity

- ▶ Group - 9 mths to December 2023 sales growth units: **devices 40% growth and SUS 22% growth** comparing with same period FY 2023
- ▶ Prior year - FY 2023 snapshot, (COVID impacted)
 - ▶ FY23 Sales **NZ\$1.6m, device installations up 15% YOY**, despite Covid lockdown in China
 - ▶ Total Revenue **NZ\$2.2m**
- ▶ Recent success in Mexico with approval to enter public health sector, and Saudi Arabia with reimbursement approval from health insurers supports new growth.

Capital Raise Offer Details

TruScreen is seeking growth capital to raise up to NZD \$2.8 million through the issue of 140,008,446 New Shares at NZ\$0.02/A\$0.0187 per share. A 31% discount of the share price at market close 9 February 2024/

Funds will be used for working capital (inventory, receivables and marketing) to capitalise on China growth and new market opportunities in China, Vietnam, Saudi Arabia and Mexico.

Cervical Cancer Elimination²

Fourth most common cancer in women worldwide

- ▶ **570,000** new cases each year
- ▶ **311,000** deaths
- ▶ Most diagnoses occur at **age 35-44**

Women in LMICS are most at risk

- ▶ **1BN+** women of screening age in LMICs
- ▶ **85%** of cases & **87%** of deaths occur in LMICs

The **World Health Organisation**

has set a target to eliminate cervical cancer by the end of the century



90% coverage of HPV Vaccination of girls (by 15 years of age)



70% coverage of screening and 90% treatment of precancerous lesions



Management of 90% of invasive cancer cases

¹ Business Market Insights, June 2023


² Cervical cancer (who.int)



contributing to WHO's 70% screening target

TruScreen Business Model

Effective co-invest model with global distribution



- ▶ APAC Cervical Cancer market to reach 4B USD by 2028 with CAGR > 7%¹

- ▶ China remains the biggest opportunity with two new national screening Guidelines

- ▶ Zimbabwe, Saudi Arabia, Mexico, Vietnam poised for growth

- ▶ Annuity revenue stream (Single Use Sensor). FY24 sales revenue growth 35%

- ▶ Large global distribution network

- ▶ Ramping up growth in China and existing markets

- ▶ Ongoing manufacturing and logistics improvements to drive COGS down

- ▶ Single visit, non-invasive, mobile screening technology, artificial intelligence enabled

- ▶ No laboratory infrastructure required; nurse administered

- ▶ Accuracy equal to, or better, than leading screening methods

- ▶ Recommended by COGA Blue Book and CSCCP, China

Executive Team

Dr. Beata Edling, Chief Executive Officer

Guy Robertson, Chief Financial Officer

Edmond Capcelea, Chief Technology Officer

Dr. Jerry Tan, Lead Commercial Manager, APAC, Americas

Key Financial Details

As of 9 February 2024

Market Cap: NZ \$12 million

Share Price: NZ\$0.028

Cash Position: NZ\$0.3 million

INVESTOR CONTACT

guyrobertson@truscreen.com

This fact sheet should be viewed in conjunction with TruScreen's latest Financial information and any accompanying NZX/ASX releases. The information presented is a snapshot and does not contain supporting information necessary to make an investment decision. It is not intended to act as a recommendation to acquire TruScreen shares. There can be no assurance that actual outcomes will not materially differ from the forward looking statements presented. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to TruScreen as at the date of this fact sheet. Except as required by law (including the NZX Listing Rules), TruScreen undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. TruScreen, its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this fact sheet.